About TissueGene
TissueGene is a company based in Rockville (United States) founded in 1999. TissueGene has raised $94.64 million across 4 funding rounds from investors including Maryland Stem Cell Research Fund. The company has 29 employees as of December 31, 2022. TissueGene offers products and services including TG-C. TissueGene operates in a competitive market with competitors including Insitro, BridgeBio, ATAI, Forge Biologics and Spark Therapeutics, among others.
- Headquarter Rockville, United States
- Employees 29 as on 31 Dec, 2022
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
- Legal Name Kolon Tissuegene, Inc.
-
Annual Revenue
$3.57 M (USD)1.63as on Dec 31, 2025
-
Net Profit
-$133.18 M (USD)-469.53as on Dec 31, 2025
-
EBITDA
Not available
-
Total Equity Funding
$94.64 M (USD)
in 4 rounds
-
Latest Funding Round
$35 M (USD), Series C
May 23, 2024
- Investors
-
Employee Count
29
as on Dec 31, 2022
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of TissueGene
TissueGene offers a comprehensive portfolio of products and services, including TG-C.
Treats osteoarthritis by reducing pain and improving knee function.
People of TissueGene
Unlock access to complete
Unlock access to complete
Leadership Team
5 people
Senior Team
1 people
Finance and Accounting
1 people
Software Development Team
1 people
Unlock access to complete
Funding Insights of TissueGene
TissueGene has successfully raised a total of $94.64M across 4 strategic funding rounds. The most recent funding activity was a Series C round of $35 million completed in May 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in TissueGene
TissueGene has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Maryland Stem Cell Research Fund.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Stem cell research startups in healthcare are funded and accelerated.
|
Locked | Locked | Locked |
Investor details for TissueGene
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by TissueGene
Investment portfolio details for TissueGene
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - TissueGene
Detailed financials for TissueGene
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Tissuegene Comparisons
Peer comparison for TissueGene
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of TissueGene
TissueGene operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Insitro, BridgeBio, ATAI, Forge Biologics and Spark Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
An AI-enabled platform is developed for infectious disease treatment.
|
|
| Locked | Locked | Locked |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| Locked | Locked | Locked |
A biopharmaceutical company accelerating innovative mental health treatments.
|
|
| Locked | Locked | Locked |
Gene therapies for rare diseases are developed to treat patients.
|
|
| Locked | Locked | Locked |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| Locked | Locked | Locked |
Provider of cell therapies to treat cancer and hematologic conditions
|
Detailed competitors of TissueGene
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Tissuegene
Complete news archive for TissueGene
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about TissueGene
TissueGene was founded in 1999 and raised its 1st funding round 18 years after it was founded.
TissueGene is headquartered in Rockville, United States. It is registered at Rockville, Maryland, United States.
Moon Noh is the current CEO of TissueGene.
TissueGene is a funded company, having raised a total of $94.64M across 4 funding rounds to date.
As of Dec 31, 2022, the latest employee count at TissueGene is 29.
Annual revenue of TissueGene is $3.57M as on Dec 31, 2025.
Founded in 1999 and based in Rockville, United States, TissueGene operates in the biotechnology sector, focusing on allogeneic cell therapies for orthopedic conditions. The lead product, TG-C, is advanced to phase III trials for cartilage regeneration in severe knee osteoarthritis through engineered human chondrocytes producing TGF-β1. Preclinical efforts target bone, disc, and nerve regeneration.
TissueGene's top competitors include Spark Therapeutics, BridgeBio and Forge Biologics.
TissueGene offers TG-C.
TissueGene has 1 investor. Key investors include Maryland Stem Cell Research Fund.